Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Germany based CFO’ operating in the Health Care space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Michael Brosnan
Chief Financial Officer of Fresenius Medical Care
Michael Brosnan was appointed chief financial officer on January 1, 2010. Previously, he served as chief financial officer of Fresenius Medical Care North America for seven years. He joined the company in 1998 as vice president of Finance and Administration for Spectra Renal Management, the company’s laboratory services organization. Subsequently, he assumed several executive functions at Fresenius Medical Care North America.Prior to joining the company, he held senior financial positions at Polaroid Corporation and was an audit partner at
Follow Michael Brosnan:
About Fresenius Medical Care: Fresenius Medical Care is a healthcare company that provides dialysis treatment for those with chronic kidney diseases.
Philip Magoulas
CFO & Co-Founder of Bestsmile
Co-founder and managing director Alexander Henn is mainly responsible for markets, marketing and business development. He first accessed the digital world during the stock market boom in 1999 with the Boersen-Investor.de exchange platform and founded the first German shop for vitamin products at the age of 15. He later founded other companies such as the online shop Libute.de and Xantera AG. This young entrepreneur graduated from high school by taking evening classes in Munich and then, in addition to his professional activity, studied law at Ludwig-Maximilians-Universität in Munich. During his free time, Alexander Henn devotes himself to politics and history and relaxes listening to classical or electronic music.
Follow Philip Magoulas:
About Bestsmile: Bestsmile is an orthodontics company that specializes in clear aligner and veneer treatments for your teeth.
Matthias Zachert
CFO of Merck
Matthias Zachert, born in 1967 in Bonn, Germany, has been a member of the Executive Board and Chief Financial Officer of Merck since June 2011. Prior to this, he served as Chief Financial Officer of Lanxess AG from 2004 to 2011, where he played a key role in establishing the global finance organization, restructuring the portfolio, and realigning the Bayer spin-off. Before joining Lanxess, as of 2002 Matthias Zachert was Chief Financial Officer at Kamps AG, where he helped to restructure the company. From 1999 to 2002, Matthias Zachert worked in Paris as Chief Financial Officer of the International Region of Aventis Pharma AG, which was formed by the merger of Hoechst Marion Roussel (HMR) and Rhône-Poulenc Rorer. Before the merger that created Aventis, Matthias Zachert held various senior management positions in the pharmaceutical business of Hoechst AG. Matthias Zachert completed an industrial management apprenticeship at Mercedes-Benz AG from 1988 to 1990. Afterwards, he studied business administration with a concentration in finance and international management from 1990 to 1995. He graduated with a degree in business administration (Diplom-Kaufmann). He is married and has three children.
Follow Matthias Zachert:
About Merck: Merck is a pharmaceutical and chemical enterprise that develops prescription drugs and over-the-counter products.
Richard Stoffelen
Chief Financial Officer of Centogene
Richard serves as CFO, providing international expertise in global financial topics at CENTOGENE. His experience and know-how supports CENTOGENE in its continued global growth plans. With over 25 years of experience in international leadership roles covering the full width of governance and risk concepts, his expertise, combined with his extensive change management skills, ensures the finance organization will enable the company to continue its expansive growth path. Richard previously served as Head of Internal Audit at Holcim, a listed multinational company in Switzerland, where he was asked to lead the change of this function from a globally distributed model to a centralized, risk based, model. From 1985 to 2013 he was active in different Audit- and Management-positions at (a.o.) KPMG, in Chicago, Frankfurt, Hong Kong and the Netherlands. During his international audit tenure, Richard was responsible for audits of a multitude of small and large (listed on various stock exchanges, including the US) clients in a wide variety of industries, including the Pharma industry. He developed a new entity on strategic alliances, where he also provided strategy consulting services, including business planning and related funding. As Partner in Charge of one of the offices, he created values-based turn-around. Subsequently, he was HR responsible in the management team for the audit practice of KPMG NL-south. This role led to a further roll out of his management development initiatives in Hong Kong, China and Germany. Furthermore, Richard was involved in IPO`s and Bond issuances on a variety of stock exchanges. He was an active public speaker during his leadership and business development regarding the role of the China Practice, both in Hong Kong-China, and in Europe – where he led the EMA China Practice. Richard graduated as a Dutch CPA with the NBA and Tilburg University – the Netherlands, with further executive education programs at Harvard Business School, Insead (Executive MBA), IMD and IESE.
Follow Richard Stoffelen:
About Centogene: CENTOGENE provides methods and technology for human genetics analysis.
Federico Bursgens
Managing Director and CFO of GNA Biosolutions
Federico holds the post of Managing Director and CFO of GNA Biosolutions. His primary responsibilities are GNA’s finances as well technology-wise for the optoelectronic and software development. Federico has started his entrepreneurial career in high school and thus gained many years of business planning experience. Federico began his undergraduate studies of physics at the University of Munster/Germany and then enrolled at the Universities of Wurzburg/Germany and the University of Texas at Austin, where he earned his Master’s degree in physics in 2003. During his entire studies Federico was a fellow of the German National Academic Foundation (Studienstiftung). Afterwards, Federico moved to Munich/Germany where he worked in the Center for nanoscience and obtained his PhD in physics from Ludwig-Maximilians-Universität in 2008. He is author and co-author of 16 peer-reviewed scientific papers on detection technology.
Follow Federico Bursgens:
About GNA Biosolutions: GNA Biosolutions is a private molecular diagnostics company.
Michael Karb
Chief Financial Officer of ottonova
Michael is chief financial officer responsible for ottonova’s finances.
Follow Michael Karb:
About ottonova: ottonova is Germany’s newest and purely digital health insurance
Anne Burger
CFO & Co-Founder of Breath Therapeutics
Anne Burger has over 15 years expertise in senior finance functions for biotech and Medtech companies throughout Europe and has served as lead advisor in numerous transactions, financings and structuring projects. Recently, Burger was CFO for Rigontec GmbH, an immune-oncology biotechnology company. She supported Rigontec’s fundraising activities and had an active role in the execution of the Trade sale to MSD (deal volume up to 464 M€). Throughout her career, Burger held several CFO and advisor positions in the life sciences and healthcare sector and was responsible for fundraising, executing trade sales and licensing agreements, and preparing for IPOs. Burger earned a graduate degree in Business Administration (Ludwig-Maximilian-Universität Munich, Honors) and successfully passed graduate studies in public health (Ludwig-Maximilian-Universität Munich).
Follow Anne Burger:
About Breath Therapeutics, Catalym: Breath Therapeutics is a private clinical-stage biopharmaceutical company.
Martin Reichhuber
Chief Financial Officer of 4TEEN4 Pharmaceuticals
Follow Martin Reichhuber:
About 4TEEN4 Pharmaceuticals: 4TEEN4 Pharmaceuticals develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions.
Oliver Schlüter
Managing Director and CFO of Novaliq
Oliver Schlüter is managing director, CFO of Novaliq. He has 20+ years of professional experience within the fields of Finance and Life Sciences. Oliver Schlüter was CFO of CureVac GmbH from 2010 to 2015. During his tenure at CureVac, he was instrumental in the transformation of a 70 employee R&D-driven company to a 170-employee customer-centric and value-focused corporation that entered into several strategic partnerships with in-house cGMP-manufacturing. From the time of his appointment in 2010, the company secured more than USD 250 million in funding and increased the company value more than tenfold to more than €1 billion. He holds a PhD in computational finance and also studied business administration.
Follow Oliver Schlüter:
About Novaliq: Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics.
Friedrich Jacobi
CFO & Managing Director of Fiagon
Dr. Jacobi serves Fiagon as the Chief Financial Officer and as a member of the Board of Directors. Friedrich spearheads Fiagon’s financial operations, overseeing Investor Relations, Financial Corporate Strategy, and Treasury. In addition, he serves as the global head of Human Resources, Legal, and Compliance. Friedrich joined Fiagon in the first quarter of 2017, bringing more than 16 years of experience in medical and life science industries. He further adds over 20 years of business administration and management experience to the executive team. Pulling from his extensive background with both startup and large companies, Friedrich offers considerable experience transitioning a company from the startup phase, into high growth, mid-capitalization, and acquisition. Most recently, Friedrich served as CFO and Business Manager for Allergopharma, the global allergy subsidiary of Merck KGaA, playing a vital role in the high growth and performance of the company during his nine-year tenure. Friedrich is a proponent of the agile business model implemented in Fiagon. He advocates a proactive management style that allows for maximizing efficient use of company resources. In line with Fiagon’s core values, Friedrich ascribes to employee empowerment methodology, seeking to support and promote employee growth. Friedrich earned his Ph.D. in Business Administration from the University of St. Gallen in St. Gallen, Switzerland. Prior to his doctoral program, he received his Master’s Degree in Business Administration from James Madison University in Virginia, USA.
Follow Friedrich Jacobi:
About Fiagon: Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation.
Jens Holstein
Chief Financial Officer of MorphoSys
Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Finance Director and Labor Director of the company’s subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London. Mr. Holstein holds a Diploma in Business Administration from University of Münster. He currently does not hold any other board memberships.
Follow Jens Holstein:
About MorphoSys: MorphoSys is a biotechnology company focused on the research and development of fully human antibodies.
Lu Alexandra Adler
CFO of Balance Yoga Institute GmbH & Co. KG
Follow Lu Alexandra Adler:
About Balance Yoga Institute GmbH & Co. KG: Balance Yoga is one of the largest on-site platforms for modern yoga, teacher training academy, yoga retreats & workshops and retail shop
Yannick Will
CFO & COO of Lindera GmbH
Yannick Will is CFO & COO responsible for finance and operations . He has a fondness for innovative business ideas with sustainable and social orientation, which he has found united at Lindera. Prior to joining Lindera, Yannick worked for two years in management consulting at Bain & Company specializing in corporate strategy, finance and process organization. As a graduate industrial engineer from the TU Berlin, he stimulates the exchange between the business management and the technical team at Lindera.
Follow Yannick Will:
About Lindera GmbH: Lindera has developed the 1st quantitative mobility self-test for seniors by analyzing the gait to prevent falls.
Wolf-Peter Werner
Co-Founder and CFO of Mecuris
Follow Wolf-Peter Werner:
About Mecuris: Mecuris develops tailor-made prostheses and orthoses from the 3D printer.
Christian Nafe
Managing Director and Chief Financial Officer of leon nanodrugs
Christian Nafe is the Managing Director & Chief Financial Officer of leon-nanodrugs.He brings in more than 25 years of successfully working in corporate finance, controlling and finance. Christian held leading management positions in different roles in worldwide operating companies, since 2000 with a focus on life sciences. During this time, he successfully managed numerous license contracts, asset and share deals as well as supply agreements. He recently served as CEO/CFO at BioNet Holding GmbH, BioNet Ventures GmbH and BioNet Pharma GmbH (former Scil Technology GmbH). Christian graduated with honors as Dipl. Kaufmann in Business Administration from University Regensburg.
Follow Christian Nafe:
About leon nanodrugs: leon-nanodrugs is a nanotechnology-based drug development company.
Melanie Hammerschmidt-Broman
Chief Financial Officer of Leica Microsystems
Follow Melanie Hammerschmidt-Broman:
About Leica Microsystems: Leica Microsystems designs and produces precision optics systems for the analysis of microstructures.
Florian Fischer
CFO of Activaero
Dr. Fischer joined Affimed in 2005 as CFO on a part-time basis, transitioning into the full time CFO position at the Company’s IPO in 2014. Florian has a strong track record in various Biotech/MedTech executive positions, as lead advisor in a variety of transactions and financings in the life sciences and healthcare sector. Dr. Fischer is founder of MedVenture Partners – a corporate finance and strategy advisory company focusing on the life sciences and healthcare industry. Dr. Fischer was Chief Financial Officer of Activaero GmbH from 2002 until 2011 and responsible for corporate development until Activaero’s acquisition by Vectura in 2014. He also served as Chief Financial Officer of Vivendy Ltd. from 2008 until 2013 and as Managing Director of AbCheck in 2009. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years until 2002, where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer is also a Director of Amphivena. He holds a graduate degree in business administration from Humboldt University, Berlin and a Ph.D. in public health from the University of Bielefeld.
Follow Florian Fischer:
About Activaero, Affimed: Activaero develops breathing technologies for patients suffering from severe respiratory diseases.
Georg Kox
Managing Director & CFO of Sividon Diagnostics
1999: project manager for the Bio-Gen-Tec-NRW state initiative; financing of promising biotech start-ups 2001: business development and license management for a medium-sized pharmaceutical company 2002: International Marketing and Sales at DASGIP AG. 2005: Investment Manager at Intelligent Venture Capital GmbH; focus on life science and technology-based start-ups. 2008: CEO of Intelligent Venture Consulting AG. Active support for entrepreneurs on strategic issues in marketing, sales and finance Since 11/2010: Managing Partner of Sividon Diagnostics GmbH
Follow Georg Kox:
About Sividon Diagnostics: Sividon Diagnostics develops advanced diagnostics that facilitate therapeutic discovery.
Thomas Taapken
CFO of InflaRx
Follow Thomas Taapken:
About InflaRx: InflaRx develops new therapeutics in the field of acute and chronic inflammation.
Anne Burger
CFO of Rigontec
Follow Anne Burger:
About Rigontec: Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
Tim Niemeyer
CFO of Promedicly
Follow Tim Niemeyer:
About Medexo, Promedicly: Promedicly is a service provided by the Society for Medical Reports UG.
Reinhard Rubow
Chief Financial Officer of Retina Implant
Reinhard Rubow worked in various leading financial functions at several well-known companies before becoming commercial director of the Institute of Natural Sciences and Medicine (NMI) at the University of Tübingen in Reutlingen. From there, he ventured into the start-up company Retina Implant AG.
Follow Reinhard Rubow:
About Retina Implant: Retina Implant is a biotech company which develops subretinal implants for partially sighted and blind patients.
Benjamin Steimle
CFO & Co-Founder of Cytena
Follow Benjamin Steimle:
About Cytena: Cytena develops single-cell printing technology for cell research and professional diagnostics.
Philipp Naegelein
Co-Founder and CFO of MEDIKURA
Follow Philipp Naegelein:
About MEDIKURA: MEDIKURA develops digital infrastructure for drug safety. The goal is to make the drug safety as safe as possible.
Peter Willinger
CFO of Apogenix
Peter Willinger is Chief Financial Officer of Apogenix. He also directs the human resources, legal/IP, quality assurance, and public relations departments at Apogenix. Before joining Apogenix, he was CFO of LION bioscience AG/SYGNIS Pharma AG in Heidelberg, Germany, where he oversaw the finance, investor relations, and corporate development departments. From 1998 to 2004, he was Director Controlling und Vice President Global Finance & Operations at LION bioscience AG. Following his studies in business administration at the Baden-Wuerttemberg Cooperative State University Mannheim, Willinger worked as a controller with Rudolf Wild GmbH in Heidelberg, Germany, for eight years before joining the finance department of LION bioscience AG.
Follow Peter Willinger:
About Apogenix: Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Rudolf Schulze Vohren
Chief Financial Officer of Nano4Imaging
Entrepreneur and Consultant highly experienced in business development. In 2011 he co-founded Nano4Imaging GmbH and, in 2007 IN LIFE Management AG. Rudolf serves IN LIFE Management AG as Chairman of the Supervisory Board. IN LIFE specializes in solving risk- and time-critical management problems in life sciences and health care through interim executives. Rudolf is Managing Director of BBM VOHREN GmbH, which he founded in 2004. BBM VOHREN is active in the area of international business development and building new ventures. During previous 18 years Rudolf worked for BAYER AG on international assignments in Asia, Africa/Middle East, Europe and Latin America. Industries served include Non-Profit-Organisations, Pharma/OTC, Biotechnology, Nanotechnology, in-vitro Diagnostics/IVD, Life Science Research, Medical Devices/MedTech, Fine Chemicals, Agrochemicals and Veterinay. Specialties: High premium on: – Acquisition of high value projects and customers – Structuring and executing (interim) management projects – Growth strategies and international market entry
Follow Rudolf Schulze Vohren:
About Nano4Imaging: Nano4Imaging produces and uses medical devices and implants visible for medical interventions to monitor their function (e.g under MRI).
Gerrit Maass
CFO of Pantherna Therapeutics
Follow Gerrit Maass:
About Pantherna Therapeutics: Pantherna Therapeutics is a privately-held biopharmaceutical company.
Gerrit Maass
CFO of Pantherna Therapeutics
Follow Gerrit Maass:
About Pantherna Therapeutics: Pantherna Therapeutics is a privately-held biopharmaceutical company.
Abdelghani Omari
Chief Financial Officer of Paion
Abdelghani Omari joined PAION in 2008 as Vice President Finance. In 2014 he was appointed Chief Financial Officer of PAION AG. Abdel has more than 17 years of experience in Finance. At KPMG, he adviced international clients on accounting, post-merger integration and financial reporting. Previously, he worked several years in the audit department of KPMG with a focus on the chemical industry. Abdel has been instrumental in PAION’s recent financing and partnering deals. He holds a degree in Business Administration from the University of Aachen.
Follow Abdelghani Omari:
About Paion: PAION is a biopharmaceutical company developing and commercializing drug candidates for diseases with substantial unmet medical needs.
Marcus Irsfeld
Chief Financial Officer of IOmx Therapeutics
Marcus is the Chief Financial Officer. He has a long-standing track record in this position either as employee or freelancer in the life science industry. Over the last years, he has been supporting several biotech and MedTech companies in different maturity stages. In 2001, he started his career in the life science industry as CFO of ProCorde GmbH which merged with Trigen in 2006. He finally took over the responsibility for the whole Trigen Group as the sole member of the executive board of Trigen Holdings AG. Before joining ProCorde, Marcus worked in different industries, including financial controller in a German Chinese joint venture in the province Shandong in China. Marcus holds a degree in Business Administration from the University in Münster, Germany. Marcus was co-founder and CFO of Averitas Pharma Inc. (NJ) which was successfully sold to Gruenenthal.
Follow Marcus Irsfeld:
About IOmx Therapeutics: iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics.
Felix Dietrich
Co-Founder & CFO of Amparo
Follow Felix Dietrich:
About Amparo: Disrupting prosthetic care technology with human-centered design.
Holger Schmoll
Chief Financial Officer of AiCuris
Holger studied economic sciences at the universities of Bochum and Hagen, focusing on finance, HR and business informatics. He started his career in the IT industry and worked as the general manager of an IT system vendor and project leader from 1990 – 2004. Later, as a senior consultant, he was responsible for re-organization and re-capitalization projects for mid-sized companies. In 2007 Holger joined AiCuris as Chief Financial Officer.
Follow Holger Schmoll:
About AiCuris: AiCuris is a pharmaceutical company that discovers, researches and develops antiviral and antibacterial agents to treat infectious diseases.
Albert Christian Schauer
Chief Financial Officer of Avra Medical Robotics
Albert Christian Schauer, BRA, CPA, CTA has been Chief Financial Officer of AVRA Surgical Robotics Inc. and serves as its Principal Accounting Officer. Albert Schauer has been President and Chief Executive Officer of PharmOptima LLC, a pre-clinical contract research company based in Portage, Michigan. He served as the Chief Executive Officer of Eimo Technologies, Inc. and also served as its Chief Financial Officer. Following almost 10 years with Ernst & Young(formerly Ernst & Ernst ) in Kalamazoo and Cleveland, he joined Clausing Corporation in 1974 as Chief Financial Officer, and served that Company for 25 years in various senior management positions, the last 15 years as Chairman and Chief Executive Officer. For the prior 15 years, he was employed by Clausing Industrial Inc., a subsidiary of The 600 Group PLC, headquartered in the United Kingdom.
Follow Albert Christian Schauer:
About Avra Medical Robotics: AVRA was organized by a senior leadership team with broad and deep experience in medical research, innovation
Matthias Klaften
COO & CFO of amcure
Matthias Klaften is one of the co-founders of amcure. As Chief Operating Officer and Chief Financial Officer, he is responsible for the operative management of amcure. He has expertise in the development of high-tech projects and has advised many biotech start-up companies as business development manager and consultant for Spin-Off projects at the department of Innovation Management at the Karlsruhe Institute of Technology (KIT). Prior to that, he was a project leader for several medtech projects funded by the Helmholtz Society, the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Technology (BMWi). Dr. Klaften received his PhD from the Institute for Experimental Genetics at the Helmholtz Zentrum München.
Follow Matthias Klaften:
About amcure: amcure is a clinical-stage company develops peptide-based compounds for the treatment of highly metastatic forms of squamous cancer.
Erika Tertilt
Group CFO of Alexianer Krefeld
Erika Tertilt is the CFO at Apleona.
Follow Erika Tertilt:
About Alexianer Krefeld: Alexianer Krefeld provides outpatient treatment, clinical services, emergency medicine, family care, neurology and rehabilitation services.
